Document is current

Article History

Received: 28 May 2025

Accepted: 7 July 2025

First Online: 23 July 2025

Declarations

:

: Andreas Pinter has served as an investigator, speaker and/or consultant for AbbVie, Almirall-Hermal, Amgen, Biogen Idec, BioNTech, Boehringer Ingelheim, Celgene, GSK, Eli Lilly and Company, Galderma, Hexal, Janssen, Leo Pharma, MC2, Medac, Merck Serono, Mitsubishi, MSD, Novartis, Pascoe, Pfizer, Tigercat Pharma, Regeneron, Roche, Sandoz Biopharmaceuticals, Sanofi Genzyme, Schering-Plough and UCB Pharma. Emanuele Trovato has served as speaker for AbbVie, Novartis, Janssen, UCB Pharma, Eli Lilly and Company, Almirall and Leo Pharma. Lluís Puig reports grants to institution from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Celgene, Janssen, Leo Pharma, Eli Lilly and Company, Novartis, Pfizer, Regeneron, Roche, Sanofi and UCB, has received consulting fees or honoraria from AbbVie, Almirall, Amgen, Baxalta, Biogen, Boehringer Ingelheim, Celgene, Gebro, Janssen, Leo Pharma, Eli Lilly and Company, Merck Serono, MSD, Mylan, Novartis, Pfizer, Regeneron, Roche, Sandoz, Samsung-Bioepis, Sanofi and UCB and participated in company-sponsored speaker’s bureau for Celgene, Janssen, Eli Lilly and Company, MSD, Novartis and Pfizer. Jose-Manuel Carrascosa reports grants, personal fees, participation on advisory boards and/or nonfinancial support from AbbVie, Almirall, Amgen, Boehringer Ingelheim, BMS, Eli Lilly and Company, Janssen, Novartis, Sandoz and Leo Pharma. Lluís Puig and Jose-Manuel Carrascosa are Editorial Board Members of Dermatology and Therapy. Lluís Puig and Jose-Manuel Carrascosa were not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Thierry Boyé reports personal fees and grants (clinical research) from Novartis, Leo Pharma, Janssen, AbbVie, Amgen, Eli Lilly and Company and UCB. Matteo Megna declares to have acted as speaker and/or consultant for AbbVie, Amgen, Almirall, Eli Lilly and Company, Janssen-Cilag, Leo Pharma, Novartis and UCB. Julia-Tatjana Maul has served as advisor and/or received speaking fees and/or participated in clinical trials sponsored by AbbVie, Almirall, Amgen, BMS, Celgene, Eli Lilly and Company, Leo Pharma, Janssen-Cilag, MSD, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi and UCB. Alan Brnabic, Silvia Sabatino and Inmaculada De La Torre are employees and minor shareholders of Eli Lilly and Company.

: The protocol, amendments and consent documentation were approved by local institutional review boards (IRB). A complete list of the ethical review board committees is available in the supplementary materials accompanying this study (see Supplementary Table S7: Ethical Review Boards). The study was registered at the European Network of Centers for Pharmacoepidemiology and Pharmacovigilance (ENCEPP24207) [] and was conducted according to International Conference on Harmonization, Good Clinical Practice guidelines and the Declaration of Helsinki. All patients were required to give informed consent for participation in the study. We confirm that the necessary central or local IRB and/or ethics committee approvals have been obtained for this multi-site, international study by United BioSource LLC (UBC). Approvals can be provided on request.